Recce Pharmaceuticals (ASX:RCE) posts positive findings from SARS-CoV-2 study

• Recce Pharmaceutical's (RCE) anti-infective drugs have demonstrated positive test results in combatting SARS-CoV-2 or, the COVID-19 virus
• The live animal studies concluded both RCE's R327 and R529 medications reduced viral load present in the blood of infected hamsters compared to a placebo group
• 40 hamsters were tested, each receiving higher or lower treatment doses of the drugs, respectively, or a placebo saline wash
• While the study offers a good indication of the potential for nasal administration of Recce’s anti-infective compounds, further testing on larger animals must be completed before it can be deemed fully safe and effective
• RCE shares are up modestly by 1.85 per cent, trading at $1.10

Read the full article on The Market Herald here.